Hiroaki Matsumoto

19PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyCancer diagnosisPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jul 21, 2025
Refining the CHAARTED Classification: Clinical Utility of a Novel Integrated Risk Stratification Model Incorporating Gleason Grade and Biochemical Markers in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Takanori Tokunaga, Keita Kobayashi, Kazuhiro Nagao

|Apr 30, 2025
Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy.

Shingo Hatakeyama, Rikiya Taoka, Jun Miki

|Feb 05, 2025
Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy.

Shuhei Hara, Wataru Fukuokaya, Jun Miki

|Oct 07, 2024
Prognostic risk score and index including the platelet-to-lymphocyte ratio and lactate dehydrogenase in patients with metastatic or unresectable urothelial carcinoma treated with immune checkpoint inhibitors.

Keita Kobayashi, Shigeru Sakano, Hiroaki Matsumoto

|Mar 01, 2024
Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort.

Masashi Kato, Masaki Shiota, Takahiro Kimura

|Dec 26, 2023
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.

Akira Yokomizo, Masaki Shiota, Futoshi Morokuma

Pageof 4

Frequent Collaborators

7 joint publications

Masaki Shiota

5 joint publications

Hideyasu Matsuyama

4 joint publications

Makito Miyake

3 joint publications

Shinichi Sakamoto